GlassScriptPhysician profile
Lisa Hirsch
NPI 1063849545
$1,695.19
in general payments reported to CMS, 2019-2025
27 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $14.63 · 2023: $144 · 2024: $513 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $323.83 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $221.80 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Novo Nordisk INC | $133.04 | 2019-2025 | Wegovy |
| Pfizer INC. | $110.96 | 2019-2025 | |
| Glaxosmithkline, LLC. | $93.20 | 2019-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $93.19 | 2019-2024 | Zepbound, Mounjaro |
| Amgen INC. | $77.82 | 2019-2025 | Evenity, Prolia |
| Viiv Healthcare Company | $74.58 | 2024-2025 | Apretude, Cabenuva |
| Abbott Laboratories | $67.38 | 2019 | |
| Exact Sciences Corporation | $60.26 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $53.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $49.57 | 2019 | |
| Aimmune Therapeutics, INC. | $37.91 | 2025 | Vowst |
| Teva Pharmaceuticals USA, INC. | $36.31 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $32.64 | 2024-2025 | Vibativ |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.97 | 2019 | |
| Convatec INC. | $26.26 | 2024 | |
| Abiomed | $23.23 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $19.54 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.57 | 2025 | |
| Circassia INC. | $17.31 | 2019 | |
| Astellas Pharma US INC | $17.16 | 2025 | Veozah |
| Seqirus USA INC | $17.00 | 2024 | Fluad, Flucelvax |
| Napo Pharmaceuticals INC | $17.00 | 2024 | Mytesi |
| Shionogi INC | $15.12 | 2019 | |
| Sanofi Pasteur INC. | $14.63 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.